Watch the latest video at foxnews.com
Researchers at the Veterans Affairs Boston Healthcare System are to begin a trial of a new nasal vaccine for Alzheimer’s disease this month, according to a report from STAT, the Pulitzer Prize-winning technology and health news portal, on Monday.
The vaccine, called NATS-9 (short for nasopharyngeal vaccine), contains synthetic fragments of bacterial toxin-assassin gene material. It was licensed last year from Phoenix-based pharma company Modern Healthcare, and the 20-patient trial will take place at the VA Boston Healthcare System.
It’s just one of dozens of drugs in development for the ailment, but it’s reportedly the most promising.